| Rank |
Status |
Study |
| 1 |
Not yet recruiting
|
Fluoxetine Prevention Trial
| Condition: |
Cognitive Dysfunction |
| Interventions: |
Drug: Fluoxetine; Drug: Placebo |
| Outcome Measures: |
Change from baseline in regional cerebral metabolism; Durability of the protective effect of fluoxetine; Change from baseline in neuropsychological (cognitive, functional) test results; Correlation between cognitive functioning and cerebral metabolism by correlating neuropsychological testing results with PET imaging; Correlation between inflammatory cytokines and cerebral metabolism by correlating blood cytokine marker levels with PET imaging |
|
| 2 |
Not yet recruiting
|
"Evaluation by Transcranial Magnetic Stimulation of the Benefit of Fluoxetine on Motor Recovery After Stroke"
| Condition: |
Cerebral Infarction |
| Interventions: |
Drug: Fluoxetine; Drug: Placebo of fluoxetine |
| Outcome Measures: |
Slope of the curve of recruitment of the PEMs; Slope of recruitment of the PEMs; Index finger force control in paretic hand under time-course of treatment of Fluoxetine; in index finger force control in non-paretic hand under time-course of treatment of Fluoxetine |
|
| 3 |
Unknown †
|
Predictors of Treatment Response to Fluoxetine in PTSD Following a Recent History of War Zone Stress Exposure
| Condition: |
Posttraumatic Stress Disorder, Combat-related |
| Interventions: |
Drug: Fluoxetine; Drug: Placebo |
| Outcome Measures: |
Clinician Administered PTSD Scale; PTSD Symptom Checklist |
|
| 4 |
Recruiting
|
A Study of Olanzapine and Fluoxetine for Treatment-resistant Depression
| Condition: |
Treatment Resistant Depression |
| Interventions: |
Drug: Olanzapine; Drug: Fluoxetine; Drug: Placebo |
| Outcome Measures: |
Mean Change from Baseline to 8 Week Endpoint in Montgomery-Äsberg Depression Rating Scale (MADRS); Mean Change from Baseline to 8 Week Endpoint in Clinical Global Impressions-Severity of Depression (CGI-S) Scale; Mean Change from Baseline to 8 Week Endpoint in the Simpson-Angus Scale (SAS); Mean Change from Baseline to 8 Week Endpoint in the Short-Form 36 Health Survey (SF-36); Mean Change from Baseline to 8 Week Endpoint in the Sheehan Disability Scale (SDS); Percentage of Participants who Achieve a Response Based on a ≥50% Reduction from Baseline in MADRS Total Score; Percentage of Participants who Achieve Remission Based on MADRS Total Score ≤10 at 8 Weeks; Mean Change from Baseline to 8 Week Endpoint in the Barnes Akathisia Scale (BAS); Mean Change from Baseline to 8 Week Endpoint in the Abnormal Involuntary Movement Scale (AIMS) |
|
| 5 |
Recruiting
|
Role of Inflammation Factors and Insulin Resistance in Major Depressive Disorder
| Condition: |
Major Depressive Disorder |
| Interventions: |
Drug: Fluoxetine + Valsartan; Drug: Fluoxetine + Placebo |
| Outcome Measures: |
Hamilton Depression Rating Scale (HDRS); fasting plasma glucose; fasting serum insulin; C-reactive Protein, and IL-6 |
|
| 6 |
Recruiting
|
Effectiveness Study to Compare Venlafaxine With Fluoxetine in the Treatment of Postmenopausal Women With Major Depression
| Condition: |
Major Depression |
| Intervention: |
Drug: venlafaxine,fluoxetine |
| Outcome Measures: |
change of 24-item Hamilton Rating Scale for Depression total score; the mean change of HAMD-24 subscale score in items 10, 11, 12, 13 (anxiety and somatizations) at endpoint |
|
| 7 |
Recruiting
|
Fluoxetine for Motor, Aphasia, and Neglect Recovery After Ischemic Stroke
| Condition: |
Stroke |
| Interventions: |
Drug: fluoxetine; Drug: placebo |
| Outcome Measures: |
Fugl-Meyer Motor Scale (FMMS); Western Aphasia Battery; Behavioral Inattention Test (BIT); Functional Independence Measure |
|
| 8 |
Recruiting
|
Fluoxetine for Motor Recovery After Acute Intracerebral Hemorrhage
| Conditions: |
Intracerebral Hemorrhage; Motor Impairment |
| Interventions: |
Drug: Fluoxetine; Drug: Placebo |
| Outcome Measures: |
Fugl Meyer Motor Scale score; Barthel Index; modified Rankin Scale; NIH Stroke Scale |
|
| 9 |
Unknown †
|
Safety and Efficacy of Fluoxetine in Pulmonary Arterial Hypertension
| Condition: |
Pulmonary Arterial Hypertension |
| Intervention: |
Drug: Fluoxetine |
| Outcome Measures: |
The primary endpoint will be change in pulmonary vascular resistance (PVR) measured by right heart catheterization after three months of therapy.; Efficacy, Safety and tolerability endpoints will include change between baseline and three month QIDS-SR depression scale, systolic and diastolic blood pressure (systemic) and tabulation of adverse events |
|
| 10 |
Recruiting
|
Hypoglycemia Associated Autonomic Failure in Type 1 Diabetes Mellitus (DM)
| Conditions: |
Type 1 Diabetes; Hypoglycemia Associated Autonomic Failure |
| Interventions: |
Drug: Fluoxetine; Drug: Placebo control |
| Outcome Measure: |
Change in Catecholamines |
|
| 11 |
Unknown †
|
Pharmacogenomics Studies of Antidepressants
| Conditions: |
Major Depressive Disorder; Antidepressive Agents; Pharmacogenetics; Venlafaxine; Fluoxetine |
| Interventions: |
Drug: Venlafaxine; Drug: Fluoxetine |
| Outcome Measures: |
Hamilton Depression Rating Scale (HDRS); C-reactive Protein and IL-6; fasting blood glucose, lipid profiles |
|
| 12 |
Recruiting
|
Developing Adaptive Treatment Strategies for Children and Adolescents With Obsessive-compulsive Disorder.
| Condition: |
Obsessive-Compulsive Disorder |
| Interventions: |
Drug: fluoxetine; Behavioral: Group cognitive-behavioral therapy |
| Outcome Measures: |
Treatment response status at week 28; Treatment response status at week 14; Predictors of treatment response at week 28 |
|
| 13 |
Not yet recruiting
|
RCT of a Neuroplasticity Agent and CI Therapy for Severe Arm Paresis After Stroke
| Condition: |
Severe Stroke With Affected Arm Motor Function |
| Interventions: |
Drug: Fluoxetine; Drug: Placebo; Procedure: eCMIT; Procedure: Usual Care |
| Outcome Measures: |
Grade 4/5 Motor Activity Log (MAL) Arm Use Scale; Grade 4/5 MAL Arm Use scale; Grade 4/5 Wolf Motor Function Test Performance Rate score |
|
| 14 |
Recruiting
|
A Positron Emission Topographic (PET) Study on Depression Patient With Electroacupuncture
| Conditions: |
Major Depressive Disorder; Depression |
| Interventions: |
Drug: Fluoxetine; Procedure: DCEAS (Hwato®/ Dongbang®); Procedure: n-CEA (Strietberger®) |
| Outcome Measures: |
HAMD-17; SDS; PET scanning; Clinical response; Remission; Latency; Adverse events |
|
| 15 |
Recruiting
|
Characterization and Sequential Pharmacotherapy of Severe Mood Dysregulation
| Condition: |
Severe Mood Dysregulation |
| Interventions: |
Drug: lisdexamfetamine; Drug: Placebo; Drug: fluoxetine |
| Outcome Measures: |
Clinical Global Impression-Improvement-Severe Mood Dysregulation; Pediatric Anxiety Rating Scale (PARS); Children's Depression Rating Scale; ADHD-IV Rating Scale; ADHD IV Rating Scale; Columbia Suicide Severity Scales; Barnes Akathisia Scale; Children's Affective Lability Scale; Physical Symptom Checklist; Revised Modified Overt Aggression Scale; Screen for Children's Affective Reactivity; Affective Reactivity Index |
|
| 16 |
Recruiting
|
Efficacy of Exposure and Response Prevention(ERP) and SSRIs in Chinese OCD Patients
| Conditions: |
Obsessive-Compulsive Disorder; Anxiety Disorders; Mental Disorders |
| Interventions: |
Drug: Fluoxetine; Drug: Sertraline; Drug: Paroxetine; Drug: Citalopram; Drug: Fluvoxamine; Behavioral: Exposure and Response Prevention |
| Outcome Measures: |
The change of Yale-Brown Obsessive-Compulsive Scale score; The change of Beck Depression Inventory(BDI-II) score; The change of Beck Anxiety Inventory(BAI) score; The change of Stress Perceived Questionnaire (PSS-10) score; The change of Behavioral Inhibition/Behavioral Activation System Scales score; The change of Barratt Impulsiveness Scale 11 (BIS-11) score; The change of Obsessive Beliefs Questionnaire-44(OBQ-44) score; The NEO-Five Factor Inventory-Revised (NEO-FFI-R); The Early Trauma Inventory Self Report-Short Form(ETISR-SF) |
|
| 17 |
Recruiting
|
Clinical Trial of Fluoxetine in Anxiety and Depression in Children, and Associated Brain Changes
| Conditions: |
Depression; Mood Disorder; Anxiety Disorder; Healthy |
| Intervention: |
|
| Outcome Measure: |
|
|
| 18 |
Recruiting
|
Comparing Treatments for Self-Injury and Suicidal Behavior in People With Borderline Personality Disorder
| Conditions: |
Borderline Personality Disorder; Suicide |
| Interventions: |
Drug: Fluoxetine; Behavioral: DBT; Drug: Citalopram |
| Outcome Measure: |
Suicidal and self-injurious behavior |
|
| 19 |
Recruiting
|
An Adaptive Treatment Strategy for Adolescent Depression-Continuation
| Condition: |
Adolescent Depression |
| Interventions: |
Drug: Fluoxetine; Behavioral: Interpersonal Psychotherapy |
| Outcome Measures: |
K-SADS-PL - baseline; change from baseline in KSADS at week 16 and 32; BDI-II-baseline; change from baseline in BDI at weeks 4/8/12/16/24/32; HRSD-baseline; change from baseline in HRSD at weeks 4/8/12/16/24/32; CSSR-S-baseline; change from baseline in CSSR-S at weeks 4/8/12/16/24/32 |
|
| 20 |
Recruiting
|
An Adaptive Treatment Strategy for Adolescent Depression
| Condition: |
Adolescent Depression |
| Interventions: |
Drug: Fluoxetine; Behavioral: Interpersonal Psychotherapy |
| Outcome Measures: |
K-SADS-PL - baseline; change from baseline in KSADS at week 16 and 32; BDI-II-baseline; change from baseline in BDI at weeks 4/8/12/16/32; HRSD-baseline; change from baseline in HRSD at weeks 4/8/12/16/32; CSSR-S-baseline; change from baseline in CSSR-S at weeks 4/8/12/16/32 |
|
